Dermatological experts discuss challenges that are associated with the use of standard and emerging treatments in special patient population.

Alopecia areata patients had higher rates of diseases including psoriasis, allergic rhinitis, asthma, and atopic dermatitis, highlighting the burden of comorbidities on patients in the US.

Experts provide practice pearls for educating patients on and using FMTs for the management of CDI.

Joseph Reilly, BS, PharmD, BCGP, reviews the positive economic impact of use of live-jslm for treatment of CDI in a hospital setting.

Experts comment on the measures that need to be taken to prevent or control the spread of CDI in the healthcare setting.

NHANES data presented at EULAR 2023 offer insight into trends in the risk of mortality over a time period beginning in 1988 and lasting through 2016.

In this episode of MEDcast, Diana Isaacs and Natalie Bellini interview Dr. Ken Fujioka, an endocrine specialist, to discuss practice guidelines on obesity treatment and the evolution of anti-obesity medications over the last decade.

In this episode of MEDcast, Diana Isaacs and Natalie Bellini interview Dr. Ken Fujioka, an endocrine specialist, to discuss practice guidelines on obesity treatment and the evolution of anti-obesity medications over the last decade.

Lemborexant was statistically similar to placebo on both day 1 and day 8 for any group in latency to persistent sleep, but superior in sleep efficiency and wake after sleep onset.

Data from the COVID-OUT trial suggests use of metformin could reduce a person's risk of developing long COVID by more than 50% relative to placebo therapy, with results also providing insight into the apparent lack of benefit with ivermectin and fluvoxamine.

This new research indicates substantial detection of lower-risk disease among patients who are considered to be health-seeking.

The biosimilars month in review highlights infliximab biosimilars data presented at Digestive Disease Week (DDW) 2023, California’s proposed plan to produce and market biosimilar insulin at production-equivalent prices, and new FDA approvals.

The analysis of the XPLORE trial suggested XSB-001 showed biosimilarity to reference ranibizumab as assessed by BCVA improvement at 8 weeks.

While most patients were interested in an online wellness program for managing their psoriatic arthritis, barriers, such as cost and fatigue, hindered their initiation of lifestyle adaptations.

Patients participating in the open-label extension trial had a few months for titration, more than 24 months for stable dosing, and a one-week follow up.

An analysis of nationwide data in Singapore suggests obesity is set to become the leading metabolic risk factor underlying acute myocardial infarction onset, overtaking hypertension and hyperlipidemia in the coming decades.

“How can we use these data to harness the power it has to do a better job of predicting clinical outcomes and looking at treatment responsiveness?” Dr. Reena Mehra asks.

Amid mass poor air quality exposure due to ongoing Canadian wildfires, Lungcast reviews air quality index, signs and symptoms of acute and long-term poor air exposure, high-risk patient populations, and the concerning future of particle pollution exposure.

This research indicates biologics may be safe for women of childbearing age, to whom they are often prescribed, as they pose an acceptable risk to fetuses/neonates.

An analysis of the ORAL Surveillance trial details the efficacy of tofacitinib relative to TNF inhibition based on history of ASCVD and baseline cardiovascular risk.

Edward Mena, MD, reviews the classification and diagnosis of PBC considering the change from the term “cirrhosis” to “cholangitis.”

Sonal Kumar, MD, MPH, provides an overview of primary biliary cholangitis (PBC) and its recent increase in prevalence, as well as common signs and symptoms.

A decision-analytic model leveraging data from the UK and Spain suggests people who experienced STEMI during COVID-19 lockdown periods could have a reduced life expectancy relative to their counterparts who experienced similar events in prepandemic periods.

Early intervention was shown to lead to better clinical responses, results which could translate to long-term improvements in psoriasis and sustained maintenance of response after withdrawal.

However, results from the Vet-COACH trial reported a significant improvement in mental health–related quality of life in the intervention group compared with the control group.